September 24, 2021

Capricor Therapeutics Announces Positive Final Data From its Phase II HOPE-2 Trial in Patients with Duchenne Muscular Dystrophy Treated with CAP-1002

PPMD is pleased to share that Capricor Therapeutics announced today positive final data from the HOPE-2 randomized, double-blind, placebo controlled clinical trial using CAP-1002 to treat patients with Duchenne. The HOPE-2 clinical trial met its…

Learn More

June 4, 2020

WATCH: Capricor’s HOPE-2 Final 12-Month Data – Webinar Recording

Capricor Therapeutics recently announced positive final 12-month results from the HOPE-2 Trial. HOPE-2 was a randomized, double-blind, placebo-controlled study focused on later-stage Duchenne patients. On June 3, 2020, Capricor joined PPMD for a webinar to…

Learn More

May 13, 2020

Capricor Announces Positive Top-Line Final Results from HOPE-2 Study

PPMD is excited to learn that Capricor Therapeutics has announced positive top-line 12-month results of the HOPE-2 clinical trial using CAP-1002 to treat non-ambulatory patients with Duchenne. Capricor has reported that the placebo patients in…

Learn More

October 9, 2019

2019 World Muscle Society Update – Day 4

This week, PPMD’s Abby Bronson, SVP of Research Strategy and Eric Camino, PhD, Director of Research and Clinical Innovation are attending the annual World Muscle Society (WMS) meeting, this year in Copenhagen, Denmark. Below, Abby…

Learn More

October 7, 2019

2019 World Muscle Society Update – Days 2 & 3

This week, PPMD’s Abby Bronson, SVP of Research Strategy and Eric Camino, PhD, Director of Research and Clinical Innovation are attending the annual World Muscle Society (WMS) meeting, this year in Copenhagen, Denmark. Below, Abby…

Learn More

July 19, 2019

WATCH: Capricor’s HOPE-2 Interim Analysis – Webinar Recording

On Wednesday, July 17, 2019, Capricor joined Parent Project Muscular Dystrophy for a webinar to update the community on Capricor’s HOPE-2 clinical program, following the company’s announcement of positive results from their interim analysis in…

Learn More

July 15, 2019

Capricor Announces Positive Results from its Interim Analysis in the HOPE-2 Trial

Capricor Therapeutics has just announced positive results from their interim analysis in the HOPE-2 Trial after placing a voluntary dosing hold earlier this year. Please join PPMD and Capricor as we host a webinar Wednesday,…

Learn More

April 30, 2019

WATCH: Capricor’s Clinical Program – Webinar Recording

On Wednesday, April 24, 2019, Capricor joined Parent Project Muscular Dystrophy for a webinar to update the community on Capricor’s HOPE2 clinical program. If you missed the live event, the recording can be found below….

Learn More

January 22, 2019

Capricor Announces Positive Outcomes from Comprehensive Multidisciplinary Meeting with FDA

Capricor Therapeutics announced that it had positive outcomes in its comprehensive multidisciplinary meeting with the FDA regarding development of the company’s novel cell therapy candidate, CAP-1002, after being placed on voluntary hold last month. To…

Learn More

December 17, 2018

End Duchenne Tour Recap: Cincinnati, OH

PPMD headed to Cincinnati, OH for our End Duchenne Tour stop on November 17, 2018. Many families and members of the Duchenne community came together to learn about the latest information and resources for Duchenne families. PPMD…

Learn More